| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S10067-007-0721-Z |
| P698 | PubMed publication ID | 17805483 |
| P50 | author | Vasant Sumethkul | Q56516177 |
| P2093 | author name string | Kitti Totemchokchyakarn | |
| Kanokrat Nantiruj | |||
| Suchela Janwityanujit | |||
| Orawan Verasertniyom | |||
| Kittiwan Choojitarom | |||
| P2860 | cites work | Prophylaxis of the antiphospholipid syndrome: a consensus report | Q28196923 |
| Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus | Q29614922 | ||
| Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients | Q33357081 | ||
| Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis | Q33358476 | ||
| Reassessing the status of antiphospholipid syndrome in systemic lupus erythematosus | Q33363443 | ||
| Significance of anti-phospholipid antibodies in patients with lupus nephritis | Q33373583 | ||
| Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance | Q33392960 | ||
| Influence of the antiphospholipid syndrome in the survival of patients with systemic lupus erythematosus | Q33490967 | ||
| Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus | Q34098573 | ||
| Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients | Q34435380 | ||
| Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome | Q35158386 | ||
| Catastrophic antiphospholipid syndrome: where do we stand? | Q35607279 | ||
| Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis | Q36747001 | ||
| Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. | Q40461525 | ||
| Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice | Q41927420 | ||
| IL-4 and T cells are required for the generation of IgG1 isotype antibodies against cardiolipin | Q43909456 | ||
| Coronary artery disease risk factors in the Johns Hopkins Lupus Cohort: prevalence, recognition by patients, and preventive practices | Q44589658 | ||
| Incidence of idiopathic deep venous thrombosis and secondary thromboembolism among ethnic groups in California. | Q45940952 | ||
| Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXV. Smoking, older age, disease activity, lupus anticoagulant, and glucocorticoid dose as risk factors for the occurrence of venous thrombosis in lupus patients | Q46443879 | ||
| Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. | Q50196335 | ||
| Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d'Etude de la Thrombose de Bretagne Occidentale. | Q50660298 | ||
| Association of anti-beta 2 glycoprotein I antibodies with lupus-type circulating anticoagulant and thrombosis in systemic lupus erythematosus | Q68008000 | ||
| Preliminary classification criteria for the antiphospholipid syndrome within systemic lupus erythematosus | Q68153286 | ||
| Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective | Q71500994 | ||
| Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus | Q78609890 | ||
| The presence of anti-phosphatidylserine/prothrombin antibodies as risk factor for both arterial and venous thrombosis in patients with systemic lupus erythematosus | Q83180906 | ||
| P433 | issue | 3 | |
| P921 | main subject | thrombosis | Q261327 |
| lupus nephritis | Q1621830 | ||
| P304 | page(s) | 345-351 | |
| P577 | publication date | 2007-09-02 | |
| P1433 | published in | Clinical Rheumatology | Q15754927 |
| P1476 | title | Lupus nephritis and Raynaud's phenomenon are significant risk factors for vascular thrombosis in SLE patients with positive antiphospholipid antibodies | |
| P478 | volume | 27 |
| Q38922218 | Contraception for adolescents with chronic rheumatic diseases |
| Q51071639 | Critical peripheral ischemia precipitated by severe episode of Raynaud's phenomenon in a patient with aPL-positive systemic lupus erythematosus, upon high titer anti-RNP seroconversion. |
| Q37778648 | Diagnostic algorithm for Raynaud’s phenomenon and vascular skin lesions in systemic lupus erythematosus |
| Q40851642 | Factors associated with thrombosis in pediatric patients with systemic lupus erythematosus |
| Q34066226 | Safety of hormonal replacement therapy and oral contraceptives in systemic lupus erythematosus: a systematic review and meta-analysis. |
| Q37947108 | The role of antimalarial agents in the treatment of SLE and lupus nephritis |
| Q37642828 | Thrombosis in systemic lupus erythematosus: risk and protection |
| Q83433554 | [What's new in clinical dermatology] |
Search more.